Home 2018-09-27T15:02:45+00:00

NyRoC – A Breakthrough in Blood Clotting Testing

An Effective, Drastically Simpler and Cheaper Test for Risk of Blood Clotting
Results in Minutes, Not Hours or Days!

NyRoC – Know Your Risk of Clotting

First DNA Aptamer-Based Point of Care Clotting Risk Test

Aptamer Diagnostic, Inc. developed Aptamer for the D-Dimer series of Fibrin Degradation Products, a CRITICAL BLOOD CLOT LEVEL INDEX. D-Dimer levels are critical when deep venous thrombosis (DVT), pulmonary embolism (PE), or disseminated intravascular coagulation (DIC) are suspected. Timely decisions regarding surgical operations or administration of medications in these life-threatening conditions warrant the quantitation of D-dimer in patient blood samples as soon as possible.

Aptamer is more stable, faster, and inexpensive to produce, and possess a longer shelf life compared to antibodies.

D-Dimer tests can eliminate or reduce the need for invasive and unnecessary imaging procedures, treatment and hospital stays when blood clotting conditions are ruled out. In other words, a negative D-Dimer test in combination with a low pre-test probability of venous thromboembolism can be used to exclude the diagnosis and thus safely reduce the number of unnecessary referrals for testing and imaging. This test can be used in clinical laboratories, physician’s office, hospitals, as well as at home.

Learn More

To Rule out the Presence of an Inappropriate Blood Clot:
Deep Vein Thrombosis (DVT)
Pulmonary Embolism (PE)
Disseminated Intravascular Coagulation (DIC)

2 Blood Drops from the Finger (No Laboratory)
No Special Preparation

When you have symptoms of a thrombotic episode or a condition that causes acute and/or chronic inappropriate blood clot formation, such as deep vein thrombosis (DVT), pulmonary embolism (PE), or disseminated intravascular coagulation (DIC), and to monitor the progress and treatment of DIC and excessive clotting conditions

A D-dimer test may be ordered when someone has symptoms of deep vein thrombosis, such as:

Leg pain or tenderness, usually in one leg
Leg swelling, edema
Discoloration of the leg
It may be ordered when someone has symptoms of pulmonary embolism such as:
Sudden shortness of breath, labored breathing
Coughing, hemoptysis (blood present in sputum)
Lung-related chest pain
Rapid heart rate

Clotting is more likely to happen in people who are older, are obese or overweight or have conditions — such as cancer or autoimmune disorders such as lupus. It’s also more likely in people whose blood is thicker than normal because too many blood cells are made by bone marrow. Genetic causes of excessive blood clotting are also important. These occur when there are changes in the genetic code of some proteins needed for clotting or proteins that work to naturally dissolve blood clots in the body.

Major general surgery
Major orthopedic surgery
Lower-extremity paralysis due to spinal cord injury
Fracture of the pelvis, hip or long bones
Multiple trauma
Chronic obstructive pulmonary disease
Cancer — all cancers increase the risk, especially if cancer has spread widely, and if it is cancer of the lung, brain, lymphoma, gynecologic system (like ovary or uterus), or gastrointestinal tract (like pancreas or stomach). In patients with cancer, chemotherapy and surgery for cancer further increase the risk.
 Prior VTE— Patients with a previous episode of VTE have a high chance of recurrence.
Age— Patients older than 40 years are at higher risk, and that risk doubles with each subsequent decade.
Obesity – people with obesity have 2 times the risk of VTE as people with normal weight, and the higher the weight, the higher the risk.
Immobility— Prolonged immobility combined with other major risk factors increases the likelihood of VTE (truck drivers and people who travel a lot).
Oral Contraceptives or estrogen treatment for menopause symptoms.
Family history of VTE— especially if this is in a first-degree relative (parent, sibling, child).
Physical inactivity.
Genetic blood conditions that affect clotting.

Women who are pregnant, or have just had a baby are at greater risk of developing a blood clot. The risk is greater in the presence of the following other factors:

Previous VTE
A genetic predisposition to VTE or a family history of VTE (especially in a first-degree relative-parent, sibling)
Obesity
Immobilization, such as bed rest and long distance travel
Twin gestation
Older maternal age
Other medical illness during pregnancy, like cancer, serious infection or toxemia/pre-eclampsia

Why DNA Aptamer-Based Test for D-Dimer?

Aptamer Diagnostic’s Aptamer discovery will lower the cost of D-Dimer testing and introduce point of care test kits for laboratories, medical care providers or at home testing.
This test is used as a screening test for thrombosis (clotting of blood) to indicate or rule out:
1. Deep Vein Thrombosis (DVT)
2. Pulmonary Embolism (PE)
3. Disseminated Intravascular Coagulation (DIC)

Therapeutic Application of Aptamers as Blood Thinners

Zudvix – First Aptamer-Based Blood Thinner

Drug development process is divided into multiple stages. It starts with basic science research for a new drug in the laboratory. This step was successfully accomplished at Aptamer Diagnostic, Inc. where we identified an aptamer based blood thinner that is a direct thrombin inhibitor with an antidote to neutralize and reverse the drug effect.

Aptamer Diagnostic, Inc. aptamer discovery does not only lower the cost of blood clotting therapy but also introduces a therapeutic drug with its antidote to neutralize the effect of the medication and avoid excessive bleeding. Both the drug and antidote are aptamer based, making them cheaper to synthesize, less batch to batch variation, and higher stability than antibody based therapies.

Learn More

Aptamer Life Science

8501 Wade Blvd. Bldg. 9, Frisco, TX 75034
Phone: 972-668-6005
Fax: 972-668-6720
Email: contact@aptamerlifescience.com